Vanrx

Vanrx Pharmasystems supplies Annex 1-compliant robotised fill-finish platforms (Microcell robocell) that let sponsors run small sterile batches with almost no operator intervention, ideal for cell therapies and clinical supply.

Country: United States

Commercial Robotic Fill-Finish

Coverage

	CN	EU	US
fill-finish-packaging	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	USD 1.5 million in financing from Export Development Canada (EDC) in 2019	edc.ca
Capacity	Cytiva expanded manufacturing capacity of aseptic filling machines by over 200% following the acquisition of Vanrx	lifesciencesbc.ca · bioprocessintl.com · biv.com
Regulatory approval	Individual Vanrx fill-finish machines, such as the SA25, have received FDA approval for use in specific biopharmaceutical manufacturing operations	bioflorida.com · cytivalifesciences.com
Production site	Original manufacturing plant was located in Burnaby, British Columbia, with operations fully transferred to a new 126,200-square-foot facility in Burnaby by the end of 2022	lifesciencesbc.ca · bctechnology.com · bioprocessintl.com · biv.com
Headcount	Over 120 associates at the time of the February 2021 acquisition by Cytiva	bctechnology.com · bioprocessintl.com · cytivalifesciences.com
Headquarters	Burnaby, British Columbia, Canada	bctechnology.com

Independent sources: bctechnology.com · bioflorida.com · bioprocessintl.com · biv.com · cytivalifesciences.com · edc.ca · lifesciencesbc.ca

Technologies

Name	Cluster	Risk
Aseptic filling lines	fill-finish-packaging	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.